Moteur de recherche d’entreprises européennes
Financement de l’UE (14,1 M €) : Réseau européen de données et de données probantes sur la santé Hor01/11/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Réseau européen de données et de données probantes sur la santé
Europe is generating huge amounts of patient-level information contained in Electronic Health Record (EHR) systems and other types of health databases. These include structured data in the form of diagnoses, medications, laboratory test results, etc., and unstructured data in clinical narratives. The Electronic Health Data in a European Network (EHDEN) Consortium leverages these vast volumes of data to improve future clinical practice and individual patient outcomes by increasing our understanding of disease and treatment pathways. EHDEN will galvanize transparent and reproducible analytics that will generate valid real-world evidence to improve patient care, and enable medical outcomes-based research at an unprecedented scale. The EHDEN Consortium provides the infrastructure and eco-system supporting disease-specific projects in the IMI Big Data for Better Outcomes (BD4BO) programme. The core of EHDEN is the use of a common data model (OMOP-CDM), standardised outcome assessment (ICHOM), and transparent open-source analytics (OHDSI). The objective of the EHDEN consortium is to provide all the necessary services that enable a distributed European data network to perform fast, scalable and highly reproducible research, while respecting privacy regulations, local data provenance and governance. This will include services and tools to perform data standardization, analytical pipelines, tools to share study results, and tools for stakeholder engagement and training. The EHDEN Consortium combines active participation of stakeholder representatives with proven experience in: a) integrating different data types, methods and technologies to utilize diverse clinical datasets; b) platform development to make methods and datasets Findable, Accessible, Interoperable and Reusable (FAIR); and c) engaging a wide variety of stakeholders, including health technology assessment agencies, regulators and patients.
| Abbvie Inc. | 0,00 € |
| Astrazeneca AB | 0,00 € |
| Bayer AG | 0,00 € |
| Boehringer Ingelheim Internationalgesellschaft mbH | 0,00 € |
| Celgene Management Sàrl | 0,00 € |
| Eli Lilly and Company Ltd. | 0,00 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 7 563 875 € |
| F. Hoffmann-LA Roche AG | 0,00 € |
| Forum des Patients Europeens | 236 250 € |
| H. Lundbeck AS | 0,00 € |
| Institut de Recherches Internationales Servier | 0,00 € |
| International Consortium for Healthoutcomes Measurement Ltd. | 341 875 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| National Institute for Health and Care Excellence | 610 000 € |
| Novartis Pharma AG | 0,00 € |
| Odysseus Data Services s.r.o. | 781 875 € |
| Pfizer Ltd. | 0,00 € |
| Sanofi-Aventis Recherche & Developpement | 0,00 € |
| Stiftelsen WHO Collaborating Centre for International Drug Monitoring | 203 750 € |
| Synapse Research Management Partners SL | 944 375 € |
| Tartu Ulikool | 309 375 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 1 606 313 € |
| THE Hyve B.V. | 881 813 € |
| UCB Biopharma | 0,00 € |
| Universidade de Aveiro | 626 250 € |
https://cordis.europa.eu/project/id/806968
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
